More than a decade ago, when we first embarked on our journey to delineate the biological function of vascular endothelial growth factor B (VEGF-B), we had a hard time comprehending why VEGF-B was needed. In mice, genetic deletion of VEGF-B seemed to be harmless, since the VEGF-B null mice, to a large extent, can still live a fairly normal life [1] . Moreover, overexpression of VEGF-B in different mouse tissues, such as the skin or skeletal muscle, did not seem to result in any obvious phenotype [2] . Due to these seemingly cometo-nothing findings, many researchers lost their scientific interests in VEGF-B. However, new discoveries on VEGF-B function have recently begun to surprise us -the latest one being that VEGF-B plays an important role in modulating fat utilization. Deeper scrutiny demonstrated that VEGF-B deficient mice display greater amount of body fat and weight due to impaired fatty acid (FA) uptake by the endothelium, as shown elegantly in a recent study from Dr Ulf Eriksson's laboratory [3] .
VEGF-B was discovered in 1996 as a VEGF homologue [4] . VEGF-B is produced as a secreted homodimer. Due to alternative splicing, the VEGF-B gene gives rise to two isoforms, VEGF-B 167 and VEGF-B 186 , which are homodimers of about 42 and 60 kDa, respectively. VEGF-B 186 can be proteolytically processed at Arg127 and give rise to a 34 kDa dimer. VEGF-B 167 has a heparinbinding domain, so that upon secretion, VEGF-B 167 binds to cell-surface heparan sulphate proteoglycans. By contrast, VEGF-B 186 does not contain the heparin-binding domain and therefore is more soluble. VEGF-B binds to vascular endothelial growth factor receptor-1 (VEGFR-1) and neuropilin-1 (NRP-1) [5, 6] . VEGF-B is expressed early during fetal development in mice, and remains abundantly expressed in most tissues and organs in adult mice, especially in the cardiac myocytes, skeletal muscles and neuronal tissues [7] . VEGF-B 167 is the predominant isoform expressed in most tissues and organs, accounting for more than 80% of the total VEGF-B transcripts, while VEGF-B 186 is expressed at lower levels and in a limited number of tissues [7] . For many years, research efforts on VEGF-B have focused on its speculated angiogenic activities, based on its high sequence homology and similar receptor binding pattern to VEGF, a prototype angiogenic factor. However, studies along this line, most of the time, led to inconsistent results [8] . Compared with the other VEGF family members, VEGF-B has received much less attention thus far.
Recent years have witnessed several advances in VEGF-B biology. First, different groups have shown that VEGF-B is a potent neuroprotective factor [8] [9] [10] . Second, it is recently recognized that VEGF-B has an ischemic myocardiumspecific angiogenic activity while being minimally angiogenic in most of the other organs [2, 11, 12] . Compared with these findings, the more recent discovery by Dr Eriksson' group, perhaps is more unexpected and striking. In this study, Hagberg et al. [3] showed that VEGF-B is a critical regulator of energy metabolism by regulating fatty acid uptake.
In their recent study, Hagberg et al. [3] provided several lines of evidence at different levels to show that VEGF-B has a unique and critical role in regulating fatty acid transportation. First, the authors conducted bioinformatic analysis of published microarray data and found that VEGF-B expression was closely associated with the expression of nuclear-encoded mitochondrial genes under different conditions in mice. This association appears to be specific to VEGF-B, since the other VEGF family members, such as VEGF and PlGF, do not display the same type of association in their expression. These observations at gene expression level thus pointed to a potential role of VEGF-B in energy metabolism. The authors then went on and verified the significance of the above observations using cultured cells, and found that, in endothelial cells, VEGF-B stimulation upregulated the expression of the fatty acid transport proteins (FATPs), which are a family of proteins needed for fatty acid transportation across the endothelium. Indeed, in a two-liquid-compartment endothelial cell culture assay, VEGF-B treatment increased trans-endothelial transfer of 14 C-labelled oleic acid from the upper to the basal liquid compartment, In the VEGF-B deficient mice, lack of VEGF-B results in decreased FATP expression, and subsequently reduces FA uptake by the endothelium. This in turn leads to decreased FA consumption by the heart, muscle and brown adipose tissue. Importantly, as a result of the impaired FA transport and utilization, the unconsumed FA are accumulated in the white adipose tissues (WATs), resulting in greater body fat mass and weight in the VEGF-B null mice. The biological consequences of the impaired FA uptake in the VEGF-B deficient hearts, muscles and BATs remain unclear. It is also unknown whether the reported survival/antiapoptotic effect of VEGF-B is linked to its FA-transport function. In addition, it remains to be studied why VEGF-B deficiency does not blunt FA uptake in the WATs, while this is true in other tissues. In vivo, Hagberg et al. found that VEGF-B deficient mice had a reduced FA uptake, leading to significantly less FA accumulation in their hearts, muscles and brown adipose tissues (BATs). Instead, due to the impaired FA transport and utilization, the unconsumed FA were shunted to white adipose tissues (WATs) npg and resulted in increased amount of body fat and weight in the VEGF-B null mice (Figure 1) . Furthermore, as a compensation for the reduced lipid utilization, the VEGF-B deficient mice had an increased glucose uptake and utilization in their hearts as an alternative source of energy. Mechanistically, the authors revealed that the effect of VEGF-B on endothelial FA uptake was mediated by Flt-1 and Nrp-1. This notion is supported by the findings that in mice lacking functional Flt-1 and Nrp1, the cardiac expression of FATPs was decreased. Indeed, the authors also found that the Nrp1 deficient mice displayed a similar defect in fatty acid uptake to peripheral tissues.
FA transportation
One common exciting aspect of all breakthroughs is that they always lead to interesting questions.
There appears to be an apparent tissue specificity of VEGF-B action in affecting fatty acid metabolism, since VEGF-B deficient mice display an impaired FA uptake in their BATs, but an increased FA uptake in their WATs. Why does VEGF-B deficiency not blunt FA uptake in the WATs, since VEGF-B is a secreted protein and can be found in the blood stream in different tissues? Are Flt-1 and Nrp-1 not expressed by the endothelium in WAT? Or, does FA uptake in WATs utilize different molecules other than VEGF-B? Furthermore, it is known that Flt-1 and Nrp-1 are expressed by many cell types. Does VEGF-B affect FA uptake in other types of cells apart from vascular endothelial cells?
It would be interesting to know the direct or indirect biological consequences of the impaired FA uptake in the VEGF-B deficient heart, muscle and BAT. VEGF-B has been shown to be a potent survival factor [8, 9] . VEGF-B treatment increased the survival of different cell types, including neurons [9, 10] , blood vessels [11] , and cardiac myocytes [13, 14] . It would be interesting to see whether the survival effect of VEGF-B is linked to its FA-transport function, or, whether they are two separate pathways. It is noteworthy that docosahexaenoic acid (DHA), one major n-3 fatty acid, is specifically required for retinal neuronal survival [15] . This has indicated a link between FA uptake and neuronal survival, in both of which VEGF-B plays an important role.
Also, it remains unclear why VEGF-B 186 , the more diffusible form of VEGF-B, was more effective than the heparinbinding form of VEGF-B, VEGF-B 167 , in inducing FATP expression. In the study by Hagberg et al., the co-expression of VEGF-B with the mitochondrial protein genes was the initial indication of a role of VEGF-B in energy metabolism. However, VEGF-B 186 is secreted and soluble and can be transported freely to different tissues through the blood stream. Instead, one would hypothesize that VEGF-B 167 , which is heparin binding and less soluble with a greater tissue specificity, might be more likely to fulfill the tissue-specific demand of FA uptake to match up with the oxidative capacity of that specific tissue.
It is particularly interesting to note that VEGF-B deficiency results in greater body fat mass and weight in mice. Given that obesity is becoming an epidemic in developed and developing countries and causes significant morbidity and mortality, it will be interesting to further delve into the expression and functional status of VEGF-B in obese patients, and to verify whether obesity in human may potentially be associated with any functional defect of VEGF-B, and if so, whether fortified VEGF-B expression could help fight against obesity. Moreover, it is known that fatty acid uptake affects numerous biological processes in the body, including cardiovascular, neurological and immune functions. It is therefore reasonable to expect that the discovery of a new critical player in lipid uptake, such as VEGF-B, might open up new therapeutic possibilities to tackle pathological lipid accumulation in obesity, diabetes, cardiovascular and other diseases.
We await the next surprise from VEGF-B.
